Skip to Content

Fenoldopam Disease Interactions

There are 5 disease interactions with fenoldopam:

Major

Fenoldopam (applies to fenoldopam) congestive heart failure

Major Potential Hazard, High plausibility.

Fenoldopam causes a dose-related fall in blood pressure that may worsen congestive heart failure. Therapy with fenoldopam should be administered cautiously in patients with heart failure. Monitoring blood pressure at regular intervals is recommended.

References

  1. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
  2. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  3. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  4. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
  5. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
View all 5 references
Major

Fenoldopam (applies to fenoldopam) glaucoma

Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Fenoldopam causes a dose-dependent increase in intraocular pressure. Therapy with fenoldopam should be administered cautiously in patients with glaucoma or intraocular hypertension. Intraocular pressure may return to baseline in 2 hours following discontinuation of fenoldopam.

References

  1. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  2. Everitt DE, Boike SC, Piltz-Seymour JR, VanCoevorden R, Audet P, Zariffa N, Jorkasky D "Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension." J Clin Pharmacol 37 (1997): 312-20
  3. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
Major

Fenoldopam (applies to fenoldopam) hypokalemia

Major Potential Hazard, High plausibility.

The use of fenoldopam is associated with hypokalemia (less than 3 mEq/L after 6 hours of infusion). Therapy with fenoldopam should be administered cautiously in patients with preexisting hypokalemia. Monitoring serum electrolytes and potassium replacement as required is recommended.

References

  1. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  2. Ruilope LM, Robles RG, Miranda B, Tovar J, Alcazar JM, Sancho J, Rodicio JL, Martinez A, Astorga A, Beck T "Renal effects of fenoldopam in refractory hypertension." J Hypertens 6 (1988): 665-9
  3. Girbes AR, Smit AJ, Meijer S, Reitsma WD "Renal and endocrine effects of fenoldopam and metoclopramide in normal man." Nephron 56 (1990): 179-85
  4. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  5. Nichols AJ, Ruffolo RR Jr, Brooks DP "The pharmacology of fenoldopam." Am J Hypertens 3 (1990): s116-9
View all 5 references
Major

Fenoldopam (applies to fenoldopam) hypotension

Major Potential Hazard, High plausibility. Applicable conditions: Cerebral Vascular Disorder

Fenoldopam may cause symptomatic hypotension that may exacerbate cerebral infarction or hemorrhage. Monitoring blood pressure closely during administration is recommended.

References

  1. Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, Emmanuel G, Weed SG, Panacek EA, Green JA "Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension." Crit Care Med 18 (1990): 502-4
  2. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
  3. White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM "Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam." J Am Coll Cardiol 11 (1988): 1118-23
  4. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  5. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  6. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  7. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
View all 7 references
Major

Fenoldopam (applies to fenoldopam) tachycardia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tachyarrhythmia

The use of fenoldopam is associated with producing dose-related compensatory tachycardia, particularly with infusion rates greater than 0.1 mcg/kg/min in adults and >0.8 mcg/kg/min in pediatric patients. Tachycardia may diminish over time, but remains substantial at higher doses. Care should be exercised when using this agent in patients at risk.

References

  1. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  2. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
  3. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  4. Holcslaw TL, Beck TR "Clinical experience with intravenous fenoldopam." Am J Hypertens 3 (1990): s120-5
  5. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  6. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
View all 6 references

Fenoldopam drug interactions

There are 255 drug interactions with fenoldopam

Fenoldopam alcohol/food interactions

There is 1 alcohol/food interaction with fenoldopam

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.